We serve Chemical Name:3-(3-carboxyphenyl)-5-methoxybenzoic acid CAS:1261905-12-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(3-carboxyphenyl)-5-methoxybenzoic acid
CAS.NO:1261905-12-7
Synonyms:3-(3-carboxyphenyl)-5-methoxybenzoic acid
Molecular Formula:C15H12O5
Molecular Weight:272.25300
HS Code:2922299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:83.83000
Exact Mass:272.06800
LogP:2.75860
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(3-carboxyphenyl)-5-methoxybenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3-carboxyphenyl)-5-methoxybenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(3-carboxyphenyl)-5-methoxybenzoic acid Use and application,3-(3-carboxyphenyl)-5-methoxybenzoic acid technical grade,usp/ep/jp grade.
Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 3-(3-carboxyphenyl)-5-methoxybenzoic acid manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 3-(3-carboxyphenyl)-5-methoxybenzoic acid supplier Chinese officials on Sunday reported a surge in new cases. 3-(3-carboxyphenyl)-5-methoxybenzoic acid vendor What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. 3-(3-carboxyphenyl)-5-methoxybenzoic acid factory Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.
